SecBot SecBot
S-3 ·Filed Nov 9, 2026

ADCT

ADC Therapeutics SA
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 4h ago SEC0000950103-26-017177
Shelf registration (potential dilution)
Actionable Insight • Neutral

Monitor the pace of selling by PIPE investors (Bain Capital, Redmile, TCG Crossover, Nantahala) as overhang could pressure the stock near-term. The company's cash runway extended into 2029 after the PIPE and debt prepayment reduces urgency for further capital.

DirectionNeutral
Confidencehigh
Horizonweeks

ZYNLONTA

◆ Mixed Named in this S-3
Impact
Phase
Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
Time to market
Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
Next catalyst
None dated

What to watchWatch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.51
T+0 close · Nov 9, 2026 · via day close
Latest settled
+5.96%
T+1 · $1.60
Vs SPY
+4.64%
α at T+1
Next horizon
T+5
in 8h
  1. T+0 · Nov 10 $1.51entry
  2. T+1 · 6d ago +5.96%α +4.64% · $1.60
  3. T+4 · todayOpen
  4. T+5 · in 8h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ADC Therapeutics filed an S-3 registration statement to register 61,000,000 common shares for resale by investors who participated in the October 2026 $86.6M PIPE. The company will not receive proceeds from share sales but may receive up to CHF 3.8M if pre-funded warrants are exercised for cash. This filing is a routine contractual obligation from the PIPE, not a new offering, and follows the company's recent debt restructuring and Q3 revenue growth.

Key Facts

  • S-3 registers 61,000,000 common shares for resale by selling shareholders from the October 2026 PIPE
  • Includes 12,911,347 common shares and 48,088,653 shares issuable upon exercise of pre-funded warrants
  • Company will not receive proceeds from share sales; may receive up to CHF 3,847,092 if pre-funded warrants exercised for cash
  • PIPE raised $86.6M at $1.42 per share and $1.324 per pre-funded warrant, closed October 22, 2026
  • Filed concurrently with Q3 2026 10-Q showing net product revenue of $21.0M, up 33% YoY
  • Registration is a contractual obligation under the securities purchase agreements, not a new capital raise

Financial Impact

Up to 61,000,000 shares registered for resale; potential cash proceeds to company of CHF 3,847,092 from warrant exercise

dilution

Risk Factors

  • Potential near-term selling pressure as PIPE investors resell registered shares into the market
  • Pre-funded warrants subject to 9.99% beneficial ownership limitations, limiting immediate exercise and share overhang
  • LOTIS-5 confirmatory trial showed Grade 5 safety imbalance (13.2% vs 4.6%) flagged by FDA as benefit-risk concern

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0000950103-26-017177
Document: dp256517_ex0501.htm0000950103-26-017177
Document: dp256517_exfilingfees.htm0000950103-26-017177
Document: dp256517_ex2301.htm0000950103-26-017177
Document: 0000950103-26-017177-index-headers.html0000950103-26-017177
Document: 0000950103-26-017177-index.html0000950103-26-017177
Document: 0000950103-26-017177.txt0000950103-26-017177

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026